64.Moffat SD, Resnick SM. Long-term measures of free testosterone predict regional cerebral blood flow patterns in elderly men.Neurobiol Aging. 2006 May 11
65.Gouras GK et al. Proc Natl Acad Sci U S A 2000 Feb 1; 97(3):1202-5
66.Tan RS. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease. Aging Male. 2003 Mar; 6(1):13-7.
67.Janowsky JS. Thinking with your gonads: testosterone and cognition. Trends Cogn Sci. 2006 Feb;10(2):77-82.
68.Holland J, Bandelow S, Hogervorst E. Testosterone levels and cognition in elderly men: a review. Maturitas. 2011;69:322-337.
69.O'Connor DB, Archer J, Hair WM, Wu FC. Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men. Physiol Behav. 2002;75:557-566.
70.Aydogan U, Aydogdu A, Akbulut H, Sonmez A, Yuksel S, Basaran Y, Uzun O, Bolu E, Saglam K. Increased frequency of anxiety, depression, quality of life and sexual life in young hypogonadotropic hypogonadal males and impacts of testosterone replacement therapy on these conditions. Endocr J. 2012 Aug 31.
71.Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med. 2011;8:3204-3213.
72.Somboonporn W., Davis S., Seif M.W. and Bell R. (2005). Testosterone for peri- and postmenopausal women. Cochrane Database of Systematic Reviews, Issue 4.
73.Rhoden EL, Averbeck MA. [Prostate carcinoma and testosterone: risks and controversies]. Arq Bras Endocrinol Metabol. 2009 Nov;53(8):956-62.
74.Cooper CS et al. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men J Urol 1998 Feb; 159(2):441-3
75.Morales A. Monitoring androgen replacement therapy: testosterone and prostate safety.J Endocrinol Invest. 2005; 28(3 Suppl):122-7
76.Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 1999 Sep 1; 59(17):4161-4
77.Morley JE. Testosterone replacement and the physiologic aspects of aging in men.Mayo Clin Proc. 2000 Jan; 75 Suppl: S83-7
78.Gould DC, Kirby RS Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?Prostate Cancer Prostatic Dis. 2006;9(1):14-8
79.Agarwal PK et al. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005 Feb; 173(2):533-6.
80.Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007 Feb 1;109(3):536-41
81.Morgentaler A et al. Testosterone therapy in men with untreated prostate cancer. Journal of Urology 2011 Apr;185(4)9.
82.Abramow M., Corvilain J.: Metabolic effects of human growth hormone in adults and children. J Ann Endocrinol (Paris) March-April 1963, 145-56.
83.Hernberg-Stahl E, Luger A, Abs R, Bengtsson BA, Feldt-Rasmussen U, Wilton P, Westberg B, Monson JP; KIMS International Board., KIMS Study Group. Pharmacia International Metabolic Database, "Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency," J Clin Endocrinol Metab. 2001 Nov;86(11):5277-81.
CONTRIBUTING PHYSICIANS & SCIENTISTS
Martin Dayton, D.O.; Medical Director, Dayton Medical Center (Florida, USA)
Robert M. Goldman, M.D., Ph.D., D.O.; Co-Founder & Chairman, American Academy of Anti-Aging Medicine; Co-Founder & Chairman, World Anti-Aging Academy of Medicine
Brad Grant D.O., past Pres., Osteopathic Physicians and Surgeons of California
James Forsythe, M.D., HMD; private practice (Nevada, USA)
Steven F. Hotze, M.D.; Director, Texas for Physicians’ and Patients’ Rights; Chief Executive Officer, Hotze Health & Wellness Center (Texas, USA)
Ronald M. Klatz, M.D., D.O.; Co-Founder & President, American Academy of Anti-Aging Medicine
Hans Kugler, Ph.D.; President & Founder, International Academy of Anti-Aging Medicine
A.Tina Miranda, M.D., MBA, private practice (Florida, USA)
Iris Breuer Mueller, M.D.; Psychiatrist, The Cantonal Hospital of Lucerne, Switzerland; University of Zurich, Switzerland
Emil K. Schandl, M.S., Ph.D., M.D., (MA), FNACB, SC(ASCP), CC(NRCC), LNC, CLD (FL, NY, CA); Director, American Metabolic Laboratories, Clinical Laboratory
C. Norman Shealy, M.D., Ph.D.; President, Holos Institutes of Health., Inc. (Missouri, USA)
Astrid Stuckelberger, MSc, Ph.D., Docent; Faculty of Medicine, University of Geneva, Switzerland; Secretary-General, International Association of Gerontology and Geriatrics – European Region; President, Geneva International Network on Aging; Expert on Aging at the United Nations and European Commission
ENDORSING ORGANIZATIONS
American Academy of Anti-Aging Medicine (A4M)
Academy of Anti-Aging Medicine - China
Asia-Oceania Federation of Anti-Aging Medicine (AOFAAM)
AustralAsian Academy of Anti-Aging Medicine (A5M)
European Society of Anti-Aging Medicine (ESAAM)
German Society of Anti-Aging Medicine (GSAAM)
German Society of Hemotoxicology
Hellenic Academy of Antiaging Medicine
Indonesian Society of Anti-Aging Medicine
International Academy of Anti-Aging Medicine
Japan Anti-Aging Medical Spa Association (JAMSA)
Japanese Society of Clinical Anti-Aging Medicine (JSCAM)
Korea Anti-Aging Academy of Medicine (KA3M)
LatinoAmerican Federation of Anti-aging Societies
Romanian Association of Anti Aging Medicine
Sociedad de Medicine Antievejenimiento y Longevidad de Gran Canaria
Society for Anti-Aging & Aesthetic Medicine Malaysia (SAAAMM)
South African Academy of Anti-Aging & Aesthetic Medicine (SA5M)
Spanish Society of Anti-Aging
Thai Academy of Anti-Aging Medicine
Anti Aging Research and Education Society, Turkey
Center for Study of Anti-Aging Medicine - UDAYANA University, Indonesia
Ukrainian Association of Preventive & Anti-Aging Medicine
World Anti-Aging Academy of Medicine (WAAAM)
DISCLAIMER
This Position Paper is intended to articulate the general policy positions of certain officers and directors of The American Academy of Anti-Aging Medicine (A4M), its numerous worldwide affiliated scientific and medical societies, and befriended organizations, and also to provide general information to practitioners and the public. This Position Paper is not intended to necessarily reflect the views of A4M’s members or the members of A4M'’s affiliated organizations. This Position Paper is also not intended to provide specific regulatory or legal advice at either the state or federal level. As state laws vary widely and individual circumstances may vary, readers are advised to consult their own legal counsel for